{"id":782361,"date":"2023-09-07T06:02:06","date_gmt":"2023-09-07T10:02:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/"},"modified":"2023-09-07T06:02:06","modified_gmt":"2023-09-07T10:02:06","slug":"fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/","title":{"rendered":"Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">RESEARCH TRIANGLE PARK, N.C., Sept.  07, 2023  (GLOBE NEWSWIRE) &#8212; Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor meetings at the conferences.<\/p>\n<p align=\"justify\">\n        <strong>Presentation Details:<\/strong>\n      <\/p>\n<p>\n        <strong>Event:\u00a0<\/strong>H.C. Wainwright Global Investment Conference in New York City<br \/><strong>Date:\u00a0<\/strong>September 12, 2023<br \/><strong>Time:\u00a0<\/strong>Company Presentation at 1:30 PM ET<\/p>\n<p>\n        <strong>Event:\u00a0<\/strong>Cantor Fitzgerald Global Healthcare Conference in New York City<br \/><strong>Date:\u00a0<\/strong>September 27, 2023<br \/><strong>Time:\u00a0<\/strong>Company Presentation at 3:35 PM ET<\/p>\n<p>For additional information, please visit the investor relations section of the Company\u2019s website at:<br \/><a href=\"https:\/\/investors.fennecpharma.com\/events-and-presentations\/events\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investors.fennecpharma.com\/events-and-presentations\/events<\/a><\/p>\n<p align=\"justify\">\n        <strong>PEDMARK\u00ae\u00a0(sodium thiosulfate injection)<\/strong><br \/>\n        <br \/>PEDMARK<sup>\u00ae<\/sup> is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is also the only therapeutic agent with proven efficacy and safety data with an established dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.<\/p>\n<p align=\"justify\">In the U.S. and Europe, it is estimated that, annually, more than 10,000 children may receive platinum-based chemotherapy. The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult, and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children that suffer ototoxicity at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.<\/p>\n<p align=\"justify\">PEDMARK has been studied by co-operative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, COG ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.<\/p>\n<p align=\"justify\">\n        <strong>About Fennec Pharmaceuticals<\/strong>\n      <\/p>\n<p align=\"justify\">Fennec Pharmaceuticals Inc.\u00a0is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK<sup>\u00ae<\/sup>\u00a0and Pedmarqsi\u2122\u00a0to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in\u00a0September 2022\u00a0and European Commission Marketing Authorization in\u00a0June 2023\u00a0for Pedmarqsi. PEDMARK has received Orphan Drug Exclusivity in the\u00a0U.S.\u00a0for seven years of market protection and Pedmarqsi has received Pediatric Use Marketing Authorization in\u00a0Europe\u00a0which includes eight years plus two years of data and market protection. Fennec has a license agreement with\u00a0Oregon Health and Science University\u00a0(OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the reduction of risk of ototoxicity induced by platinum chemotherapy, in humans. For more information, please visit <a href=\"http:\/\/www.fennecpharma.com\" rel=\"nofollow noopener\" target=\"_blank\">www.fennecpharma.com<\/a>.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>Except for historical information described in this press release, all other statements are forward-looking. Words such as \u201cbelieve,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cwill,\u201d or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about our business strategy, timeline, and other goals, plans and prospects, including our commercialization plans respecting PEDMARK<sup>\u00ae<\/sup>, the market opportunity for and market impact of PEDMARK<sup>\u00ae<\/sup>, its potential impact on patients and anticipated benefits associated with its use, and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company\u2019s business that could cause actual results to vary, including the risks and uncertainties that regulatory and guideline developments may change, scientific data and\/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Company\u2019s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company\u2019s products will not be as large as expected, the Company\u2019s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, our ability to obtain necessary capital when needed on acceptable terms or at all, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company\u2019s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2022. Fennec disclaims any obligation to update these forward-looking statements except as required by law.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.<\/em>\n      <\/p>\n<p>\n        <strong>For further information, please contact:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Robert Andrade<br \/>Chief Financial Officer<br \/>Fennec Pharmaceuticals Inc.<br \/>(919) 246-5299<\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Elixir Health Public Relations<br \/>Lindsay Rocco<br \/>(862) 596-1304<br \/><u>lrocco@elixirhealthpr.com<\/u><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODAxMCM1ODAyNjE1IzIwODk4NTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTg3NzhlODYtOGY4MS00ZmMyLTljMDctYjU0ZjY5MGRkNGVhLTExMDE0MjI=\/tiny\/Fennec-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2023 (GLOBE NEWSWIRE) &#8212; Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor meetings at the conferences. Presentation Details: Event:\u00a0H.C. Wainwright Global Investment Conference in New York CityDate:\u00a0September 12, 2023Time:\u00a0Company Presentation at 1:30 PM ET Event:\u00a0Cantor Fitzgerald Global Healthcare Conference in New York CityDate:\u00a0September 27, 2023Time:\u00a0Company Presentation at 3:35 PM ET For additional information, please visit the investor relations section of the Company\u2019s website at:https:\/\/investors.fennecpharma.com\/events-and-presentations\/events PEDMARK\u00ae\u00a0(sodium thiosulfate injection) PEDMARK\u00ae is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-782361","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2023 (GLOBE NEWSWIRE) &#8212; Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor meetings at the conferences. Presentation Details: Event:\u00a0H.C. Wainwright Global Investment Conference in New York CityDate:\u00a0September 12, 2023Time:\u00a0Company Presentation at 1:30 PM ET Event:\u00a0Cantor Fitzgerald Global Healthcare Conference in New York CityDate:\u00a0September 27, 2023Time:\u00a0Company Presentation at 3:35 PM ET For additional information, please visit the investor relations section of the Company\u2019s website at:https:\/\/investors.fennecpharma.com\/events-and-presentations\/events PEDMARK\u00ae\u00a0(sodium thiosulfate injection) PEDMARK\u00ae is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin &hellip; Continue reading &quot;Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-07T10:02:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODAxMCM1ODAyNjE1IzIwODk4NTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2023-09-07T10:02:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\\\/\"},\"wordCount\":878,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODAxMCM1ODAyNjE1IzIwODk4NTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\\\/\",\"name\":\"Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODAxMCM1ODAyNjE1IzIwODk4NTE=\",\"datePublished\":\"2023-09-07T10:02:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODAxMCM1ODAyNjE1IzIwODk4NTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODAxMCM1ODAyNjE1IzIwODk4NTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/","og_locale":"en_US","og_type":"article","og_title":"Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2023 (GLOBE NEWSWIRE) &#8212; Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor meetings at the conferences. Presentation Details: Event:\u00a0H.C. Wainwright Global Investment Conference in New York CityDate:\u00a0September 12, 2023Time:\u00a0Company Presentation at 1:30 PM ET Event:\u00a0Cantor Fitzgerald Global Healthcare Conference in New York CityDate:\u00a0September 27, 2023Time:\u00a0Company Presentation at 3:35 PM ET For additional information, please visit the investor relations section of the Company\u2019s website at:https:\/\/investors.fennecpharma.com\/events-and-presentations\/events PEDMARK\u00ae\u00a0(sodium thiosulfate injection) PEDMARK\u00ae is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin &hellip; Continue reading \"Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-07T10:02:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODAxMCM1ODAyNjE1IzIwODk4NTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences","datePublished":"2023-09-07T10:02:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/"},"wordCount":878,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODAxMCM1ODAyNjE1IzIwODk4NTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/","name":"Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODAxMCM1ODAyNjE1IzIwODk4NTE=","datePublished":"2023-09-07T10:02:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODAxMCM1ODAyNjE1IzIwODk4NTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODAxMCM1ODAyNjE1IzIwODk4NTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fennec-pharmaceuticals-to-participate-in-upcoming-investor-conferences-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=782361"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782361\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=782361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=782361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=782361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}